Oxirane is a three-membered ring compound consisting of one oxygen atom and two carbon atoms. Oxirane is present in natural products such as cryptocin, which has anticancer properties, and azidomycin, trienone, and epoxidomycin, which have shown activity against drug-resistant leukemias and AIDS-related lymphomas. Other oxirane containing bioactive molecules have anti-inflammatory, immunosuppressive, and antitumor activities. Oxiranes are a strained ring susceptible to various nucleophilic, ring-opening or rearrangement reactions, so they are considered to be one of the most important intermediates in organic synthesis.
When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.
The FDA has granted accelerated approval to selpercatinib (Retevmo; Eli Lilly and Company) for pediatric patients aged 2 years and older with RET-altered metastatic thyroid cancer or solid tumors, the federal agency announced in a press release. Selpercatinib is a highly selective, potent RET inhibitor. It works by blocking a type of enzyme (kinase) and helps prevent the cancer cells from growing.